Research ExplorerPublicationsCOVID-19-related medicine utilization study in pregnancy: Th...

COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort

Standard

COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort. / Favre, Guillaume; Gerbier, Eva; Maisonneuve, Emeline; Pomar, Léo; Winterfeld, Ursula; Lepigeon, Karine; Bloemenkamp, Kitty W M; de Bruin, Odette; Eimir, Hurley; Nordeng, Hedvig; Siiskonen, Satu J; Sturkenboom, Miriam C J M; Baud, David; Panchaud, Alice; COVI-PREG and CONSIGN group.

In: BRIT J CLIN PHARMACO, Vol. 89, No. 5, 05.2023, p. 1560-1574.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Favre, G, Gerbier, E, Maisonneuve, E, Pomar, L, Winterfeld, U, Lepigeon, K, Bloemenkamp, KWM, de Bruin, O, Eimir, H, Nordeng, H, Siiskonen, SJ, Sturkenboom, MCJM, Baud, D, Panchaud, A & COVI-PREG and CONSIGN group 2023, 'COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort', BRIT J CLIN PHARMACO, vol. 89, no. 5, pp. 1560-1574. https://doi.org/10.1111/bcp.15611

APA

Favre, G., Gerbier, E., Maisonneuve, E., Pomar, L., Winterfeld, U., Lepigeon, K., Bloemenkamp, K. W. M., de Bruin, O., Eimir, H., Nordeng, H., Siiskonen, S. J., Sturkenboom, M. C. J. M., Baud, D., Panchaud, A., & COVI-PREG and CONSIGN group (2023). COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort. BRIT J CLIN PHARMACO, 89(5), 1560-1574. https://doi.org/10.1111/bcp.15611

Vancouver

Favre G, Gerbier E, Maisonneuve E, Pomar L, Winterfeld U, Lepigeon K et al. COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort. BRIT J CLIN PHARMACO. 2023 May;89(5):1560-1574. https://doi.org/10.1111/bcp.15611

Bibtex

@article{4e5e7cb37f094019ba6d6fc9b3e47cd6,
title = "COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort",
abstract = "AIM: The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.METHODS: Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).FINDINGS: We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.CONCLUSION: Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.",
author = "Guillaume Favre and Eva Gerbier and Emeline Maisonneuve and L{\'e}o Pomar and Ursula Winterfeld and Karine Lepigeon and Bloemenkamp, {Kitty W M} and {de Bruin}, Odette and Hurley Eimir and Hedvig Nordeng and Siiskonen, {Satu J} and Sturkenboom, {Miriam C J M} and David Baud and Alice Panchaud and {COVI-PREG and CONSIGN group} and Kurt Hecher and Ann-Christin Tallarek",
note = "{\textcopyright} 2022 British Pharmacological Society.",
year = "2023",
month = may,
doi = "10.1111/bcp.15611",
language = "English",
volume = "89",
pages = "1560--1574",
journal = "BRIT J CLIN PHARMACO",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort

AU - Favre, Guillaume

AU - Gerbier, Eva

AU - Maisonneuve, Emeline

AU - Pomar, Léo

AU - Winterfeld, Ursula

AU - Lepigeon, Karine

AU - Bloemenkamp, Kitty W M

AU - de Bruin, Odette

AU - Eimir, Hurley

AU - Nordeng, Hedvig

AU - Siiskonen, Satu J

AU - Sturkenboom, Miriam C J M

AU - Baud, David

AU - Panchaud, Alice

AU - COVI-PREG and CONSIGN group

AU - Hecher, Kurt

AU - Tallarek, Ann-Christin

N1 - © 2022 British Pharmacological Society.

PY - 2023/5

Y1 - 2023/5

N2 - AIM: The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.METHODS: Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).FINDINGS: We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.CONCLUSION: Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.

AB - AIM: The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.METHODS: Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).FINDINGS: We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.CONCLUSION: Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.

U2 - 10.1111/bcp.15611

DO - 10.1111/bcp.15611

M3 - SCORING: Journal article

C2 - 36417423

VL - 89

SP - 1560

EP - 1574

JO - BRIT J CLIN PHARMACO

JF - BRIT J CLIN PHARMACO

SN - 0306-5251

IS - 5

ER -